PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Gannex Pharma Co., Ltd.

USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07F (Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Gannex ranks #46,960 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 2 technology areas.

#46,960
of 49,997 US assignees by volume
Top 37%
by Innovation Score (40.1/100)
14.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R46960 · Foreign Corporation #46,960 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #46,960/49,997
  • PHOTO-FINISH Gaindu S L
  • CPC-NARROW C07F · 2 areas
  • INNOV-PAR 40.1/100
  • CLAIMS-RICH 14.8 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2022–2024 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Gaindu, S.L. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Gannex’s 40.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Gannex

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Gannex's Innovation Score is 40.1/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Gannex?

Each dot is one of Gannex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Gannex’s own 14.8 claims/patent is ABOVE the 6.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Gannex vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 05101520 Granted patents (volume) Avg claims / patent Gaindu, S.L. - 5, 18Gaindu S LGalemed Corporation - 5, 6.2GalemedGamania Digital Entertainment Co., Ltd. - 5, 6.6Gamania Digital E…Ganado Technologies Corp. - 5, 9.8GanadoGansu Electric Power Corporation Wind Power Technology Center - 5, 4.8Gansu Electric Po…Garnet Biotherapeutics, Inc. - 5, 8.4Garnet Biotherape…Garraith Ltd. - 5, 1GarraithGateway Autoart Japan Corporation - 5, 10.4Gateway Autoart J…Gannex Pharma Co., Ltd. - 5, 14.8Gannex Pharma
Gannex vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Gannex's grants concentrate

Gannex Pharma Co., Ltd. is a focused PatentsView assignee: 2 CPC subclasses with 60% of grants classified under C07F (Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2022. By volume, Gannex sits between Gaindu, S.L. and Gateway Autoart Japan Corporation.

Gannex's three-year grant acceleration

Gannex Pharma Co., Ltd. shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Gannex's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Gannex holds 5 patents at rank #46,958, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Gannex

By rank, the assignees closest to #46,958 in granted patent volume.

Leaders in C07F (Acyclic)

Other assignees with the most granted patents in Gannex's primary technology class.

Gannex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 202220232024 1
USPTO utility patent grants by year · 2022–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table
Gannex Pharma Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2022 1 20.0%
2023 3 60.0%
2024 1 20.0%

Which technologies does Gannex Pharma Co., Ltd. patent most?

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Gannex Pharma Co., Ltd.'s patent record in context - here's where to go next.

  • Gannex Pharma Co., Ltd.'s lead technology class is C07F (Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium), 60% of its portfolio - see every assignee active in that class. Explore C07F
  • Ranked #46,960 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Gannex Pharma Co., Ltd. against Gaindu, S.L., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 40.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.